Page 1933 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 111 Principles of Red Blood Cell Transfusion 1713

the consequences of blood unavailability after national disasters SUGGESTED READINGS
involving large-scale injuries, blood substitutes could play a key role
as an immediate treatment option. In addition to these acute emer- Amberson WR, Mulder AG, Steggerda FR, et al: Mammalian life without
gency situations, there is a wide range of less urgent applications red blood corpuscles. Science 78(2014):106–107, 1933.
where oxygen carriers might provide a viable solution to difficult situ- American Society of Anesthesiologists Task Force on Perioperative Blood
ations, including supporting solid organ perfusion during transport/ Management: Practice guidelines for perioperative blood management: an
storage, augmenting perioperative hemodilution, transfusion of updated report by the American Society of Anesthesiologists Task Force
patients who refuse human blood components because of religious on Perioperative Blood Management. Anesthesiology 122(2):241–275,
beliefs (e.g., Jehovah’s Witnesses), transfusion of patients with rare 2015.
blood types or antibodies to high incidence antigens, organ preserva- Ashworth A, Klein AA: Cell Salvage as part of a blood conservation strategy
tion for transplant surgery, transfusion in patients with autoimmune in anesthesia. Br J Anaeth 105(4):401–416, 2010.
hemolytic anemia in whom it is difficult to detect underlying anti- Bell EF, Strauss RG, Widness JA, et al: Randomized trial of liberal versus
bodies, and reducing alloimmunization risk in patients receiving restrictive guidelines for red blood cell transfusion in preterm infants.
frequent transfusions. Since blood transfusion therapy is not available Pediatrics 115(6):1685–1691, 2005.
to handle some of these indications, there remains an unmet medical Vamvakas EC, Blajchman MA: Transfusion-related immunomodulation
need for a safe and efficacious RBC substitute. (TRIM): an update. Blood Rev 21(6):327–348, 2007.
Chou S, Jackson T, Vege S, et al: High prevalence of red blood cell alloim-
munization in sickle cell disease despite transfusion from Rh-matched
Red Blood Cells Derived From Stem Cells minority donors. Blood 122(6):1062–1071, 2013.
Dzik WH, Anderson JK, O’Neill EM, et al: A prospective, randomized
Due to the threat of future blood shortages, the possible shortening clinical trial of universal WBC reduction. Transfusion 42(9):1114–1122,
of RBC storage, and unlikely availability of RBC substitutes in clini- 2002.
cal use, a new source of RBCs is needed. Blood substitutes will not Fergusson DA, Hebert P, Hogan DL, et al: Effect of fresh red blood cell
answer this need in the near future. The generation of RBCs derived transfusion on clinical outcomes in premature, very low-birth-weight
from stem cells could meet this need, and this method is currently infants: the ARIPI randomized trial. JAMA 308(14):1443–1451, 2012.
under intense development by researchers worldwide. Giarratana MC, Rouard H, Dumont A, et al: Proof of principle for transfu-
Umbilical cord blood is an accessible source of stem cells with pro- sion of in vitro-generated red blood cells. Blood 118(19):5071–5079,
liferative capacity; however, the proliferation is not infinite, requiring 2011.
a system of production in batches. Neildez-Nguyen et al first reported Goodnough LT, Rudnick S, Price TH, et al: Increased preoperative collec-
the possibility of converting umbilical cord stem cells into erythroid tion of autologous blood with recombinant human erythropoietin: a
progenitors that can continue to mature into terminally differentiated controlled trial. N Engl J Med 321(17):1163–1168, 1989.
RBCs in vivo. Giarratana et al subsequently demonstrated that adult Hebert PC, Wells G, Blajchman MA, et al: A multicenter, randomized
mobilized hematopoietic stem progenitor cells can also be differenti- controlled clinical trial of transfusion requirements in critical care. N
ated into RBCs and found that the survival of the cultured RBCs Engl J Med 340(6):409–417, 1999.
was similar to that of native RBCs. Under optimized expansion and Hendrickson JE, Tormey CA, Shaz BH: Red blood cell alloimmunization
differentiation conditions, Giarratana et al reported that they were mitigation strategies. Transfus Med Rev 28(3):137–144, 2014.
able to generate 4 to 30 million RBCs from one hematopoietic stem Hod EA, Brittenham GM, Billote GB, et al: Transfusion of human voluteers
progenitor cell obtained from apheresis donors. While this expansion with older, stored red blood cells produces extravascular hemolysis
scheme could be adequate to generate clinically useful transfusable and circulating non-transferrin bound iron. Blood 118(25):6675–6682,
RBCs, it may not justify the donor risks (e.g., G-CSF–mobilized 2011.
apheresis collection) for the sole purpose of RBC production. Stem Hod EA, Zhang N, Sokol SA, et al: Transfusion of red blood cells after
cells cultured from umbilical cords would necessitate the use of cord prolonged storage produces harmful effects that are mediated by iron and
blood banks and would still be dependent on human donation. Alter- inflammation. Blood 115(21):4284–4292, 2010.
natively, embryonic stem cells and induced pluripotent stem cells Holcomb JB, Tilley BC, Baraniuk S, et al: Transfusion of plasma, platelets,
(iPSCs) can be obtained, generated, then maintained indefinitely in and red blood cells in a 1 : 1 : 1 vs a 1 : 1 : 2 ratio and mortality in patients
culture, thus providing an unlimited source of cells. Like embryonic with severe trauma: the PROPPR randomized clinical trial. JAMA
stem cells, iPSCs are capable of in vitro self-renewal and differentia- 313(5):471–482, 2015.
tion into cell types from all germ layers. However, they possess an King KE, Ness PM: Treatment of Autoimmune Hemolytic Anemia. Semin
advantage over embryonic cells in that they pose no ethical dilemma Hematol 42(3):131–136, 2005.
and can be selected based on known phenotypes. Researchers have Kirpalasni H, Whyte RK, Andersen C, et al: The premature infants in need
been able to demonstrate that iPSCs can differentiate into terminally of tranfusion (PINT) study: a randomized, controlled trial of a restrictive
mature and fully functional red cells. (low) versus liberal (high) transfusion threshold for extremely low birth
A number of challenges must be overcome before we have an weight infants. J Pediatr 149(3):301–307, 2006.
unlimited supply of clinical grade RBCs. The ideal choice for the Klein HG: Transfusion-associated graft-versus-host disease: less fresh blood
initial cell type (e.g., hematopoietic stem cell, erythroblast, etc.) and more gray (Gy) for an aging population. Transfusion 46(6):878–880,
remains to be determined. The method of reprogramming the cells 2006.
must be established to avoid the risk of potential mutation and tumor Klein HG, Anstee DJ: Mollison’s Blood Transfusion in Clinical Medicine, ed
development (although this is less of an issue for red cells as they are 11, Malden, MA, 2005, Blackwell Publishing, p 389.
enucleate and can be safely irradiated) while still ensuring the func- Lee AC, Reduque LL, Luban NLC, et al: Transfusion-associated hyperka-
tionality of the end product. Finally, the use of GMP conditions for lemic cardiac arrest in pediatric patients receiving massive transfusions.
mass production within a reasonable amount of time and at a reason- Transfusion 54(1):244–254, 2014.
able cost seems to be the greatest hurdle to date. The current chal- Mazurier C, Douay L, Lapillonne H: Red blood cells from induced
lenges in utilizing iPSCs to generate RBCs are the inefficiency in pluripotent stem cells: hurdles and developments. Curr Opin Hematol
erythroid commitment and the suboptimal cellular amplification. A 18(4):249–253, 2011.
number of strategies are under development to solve this crucial Meryman HT, Hornblower M: A method for freezing and washing red blood
problem. Until mass amplification is possible, the iPSCs could be cells using high glycerol concentration. Transfusion 12(3):145–156,
developed, not as an unlimited supply, but as a source of cells express- 1972.
ing a rare blood group used to treat alloimmunized patients with rare Natanson C, Kern SJ, Lurie P, et al: Cell-free Hb-based blood substitutes
blood types. Currently, the available methods for ex vivo manufactur- and risk of myocardial infarction and death, a meta-analysis. JAMA
ing of RBCs for clinical use are expensive and unrealistic. 299(19):2304–2312, 2008.